enGene (NASDAQ:ENGN – Get Free Report) and Bioxytran (OTCMKTS:BIXT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.
Earnings and Valuation
This table compares enGene and Bioxytran”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| enGene | N/A | N/A | -$117.30 million | ($2.17) | -0.81 |
| Bioxytran | N/A | N/A | -$2.12 million | ($0.02) | -1.42 |
Profitability
This table compares enGene and Bioxytran’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| enGene | N/A | -56.06% | -45.64% |
| Bioxytran | N/A | N/A | -737.48% |
Risk and Volatility
enGene has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Comparatively, Bioxytran has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for enGene and Bioxytran, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| enGene | 2 | 8 | 4 | 0 | 2.14 |
| Bioxytran | 0 | 0 | 0 | 0 | 0.00 |
enGene presently has a consensus target price of $11.05, suggesting a potential upside of 531.17%. Given enGene’s stronger consensus rating and higher probable upside, equities research analysts clearly believe enGene is more favorable than Bioxytran.
Insider and Institutional Ownership
64.2% of enGene shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 70.0% of Bioxytran shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
enGene beats Bioxytran on 6 of the 11 factors compared between the two stocks.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
About Bioxytran
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
